Heartland Advisors Inc. Buys Shares of 300,000 Opko Health Inc. (OPK)

Heartland Advisors Inc. bought a new stake in shares of Opko Health Inc. (NASDAQ:OPK) in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor bought 300,000 shares of the biotechnology company’s stock, valued at approximately $2,058,000. Heartland Advisors Inc. owned about 0.05% of Opko Health at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in OPK. Credit Suisse AG increased its holdings in Opko Health by 122.0% in the 1st quarter. Credit Suisse AG now owns 746,958 shares of the biotechnology company’s stock valued at $5,976,000 after buying an additional 410,445 shares during the period. State Street Corp grew its holdings in shares of Opko Health by 40.3% in the 1st quarter. State Street Corp now owns 10,926,560 shares of the biotechnology company’s stock worth $87,412,000 after purchasing an additional 3,138,685 shares during the last quarter. Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD grew its holdings in shares of Opko Health by 14.8% in the 2nd quarter. Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD now owns 135,401 shares of the biotechnology company’s stock worth $910,000 after purchasing an additional 17,458 shares during the last quarter. State Board of Administration of Florida Retirement System grew its holdings in shares of Opko Health by 7.5% in the 2nd quarter. State Board of Administration of Florida Retirement System now owns 400,278 shares of the biotechnology company’s stock worth $2,634,000 after purchasing an additional 27,940 shares during the last quarter. Finally, Paloma Partners Management Co grew its holdings in shares of Opko Health by 70.1% in the 1st quarter. Paloma Partners Management Co now owns 160,970 shares of the biotechnology company’s stock worth $1,288,000 after purchasing an additional 66,327 shares during the last quarter. Hedge funds and other institutional investors own 22.46% of the company’s stock.

Opko Health Inc. (NASDAQ OPK) opened at 6.73 on Wednesday. The firm’s market capitalization is $3.76 billion. The firm’s 50-day moving average is $6.71 and its 200-day moving average is $6.62. Opko Health Inc. has a 52-week low of $5.85 and a 52-week high of $12.15.

Opko Health (NASDAQ:OPK) last released its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.04) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.05) by $0.01. The company had revenue of $314.20 million for the quarter, compared to analysts’ expectations of $322.64 million. Opko Health had a negative return on equity of 3.34% and a negative net margin of 3.79%. The business’s quarterly revenue was down 12.0% compared to the same quarter last year. During the same period in the previous year, the business posted $0.02 earnings per share. On average, equities analysts expect that Opko Health Inc. will post ($0.18) earnings per share for the current year.

Several research firms have recently weighed in on OPK. Cantor Fitzgerald set a $20.00 target price on shares of Opko Health and gave the stock a “buy” rating in a report on Wednesday, October 25th. Zacks Investment Research raised shares of Opko Health from a “sell” rating to a “hold” rating in a report on Thursday, October 26th. Ladenburg Thalmann Financial Services reaffirmed a “buy” rating and issued a $16.00 target price on shares of Opko Health in a report on Monday, September 25th. BidaskClub raised shares of Opko Health from a “sell” rating to a “hold” rating in a report on Saturday, September 23rd. Finally, J P Morgan Chase & Co lowered shares of Opko Health from an “overweight” rating to a “neutral” rating and lowered their target price for the stock from $12.00 to $7.00 in a report on Thursday, September 14th. Four research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $13.97.

ILLEGAL ACTIVITY NOTICE: This story was first published by Community Financial News and is owned by of Community Financial News. If you are reading this story on another website, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this story can be read at https://www.com-unik.info/2017/11/01/heartland-advisors-inc-buys-shares-of-300000-opko-health-inc-opk.html.

In related news, CEO Phillip Md Et Al Frost acquired 18,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 9th. The shares were bought at an average cost of $6.35 per share, with a total value of $114,300.00. Following the completion of the purchase, the chief executive officer now directly owns 3,068,951 shares in the company, valued at $19,487,838.85. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last ninety days, insiders purchased 667,300 shares of company stock worth $4,031,059. 40.19% of the stock is owned by insiders.

About Opko Health

OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.

Institutional Ownership by Quarter for Opko Health (NASDAQ:OPK)

What are top analysts saying about Opko Health Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Opko Health Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit